Notwithstanding the result in the first HyBryte™ (SGX301) Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma and the Phase 2a clinical trial of SGX302 for the treatment of psoriasis ...

Mycosis fungoides was the first type of lymphoma to be treated with radiation (Scholz, 1902). Since its use in the early 1900s, technical advances have led to the development of electron beam ...

Persistent itchy skin is usually harmless, but doctors warn it can sometimes be linked to certain cancers. Here are four ...

Persistent itching can sometimes signal serious illness, including cancer. Oncologist Dr Amit Garg highlights four ...

PRINCETON, N.J., Sept. 30, 2025 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing ...

PRINCETON, N.J., Oct. 7, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...

BERKELEY HEIGHTS, N.J., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Secura Bio, Inc. (www.securabio.com), an integrated pharmaceutical company maximizing commercial outcomes for oncology medicines, today ...

PRINCETON, N.J., Oct. 14, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...

Dermatology Nursing. 2006;18(6):566-575. IA: <10% body surface area involved, flat or slightly raised skin lesions; no skin tumors, no lymph nodes or visceral involvement IB: >10% body surface area ...

Phase 3 clinical study of HyBryte™ in CTCL initiating in 2024 Comprised of internationally renowned physicians with extensive experience in treating and running clinical research trials in CTCL, this ...